This paper compared the concentration, size distribution, and KRAS mutation frequency of cell-free DNA (cfDNA) from plasma and serum. The effects of the amount of DNA >800 bp, white blood cell (WBC) counts, and neutrophil counts on the fraction of DNA with KRAS mutations were also investigated.
Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction.
Lee JS, Kim M, Seong MW, Kim HS, Lee YK, Kang HJ
Purpose
Conclusion
Although the mean concentration of DNA was higher from serum than plasma specimens, this was likely attributable to genomic contamination as there was no difference in concentration of DNA fragments of 50-800 bp but significantly more DNA >800 bp in serum specimens. KRAS mutations were identified in a lower percentage of serum than plasma specimens and the median mutation fraction was also lower in serum than plasma specimens. The difference in KRAS mutant fraction between the plasma and serum specimens was modestly correlated with the amount of DNA >800 bp, the WBC count, and the neutrophil count; indicating that dilution of cfDNA with genomic DNA is a likely source for the underestimation of KRAS mutation frequency in serum.
Studies (1)
Purpose
This study compared the concentration, size distribution, and KRAS mutation frequency of cell-free DNA (CfDNA) from plasma and serum. The effects of the amount of DNA >800 bp, WBC counts, and neutrophil counts on the fraction of DNA with KRAS mutations were also investigated. Blood was collected simultaneously into EDTA Vacutainer and VACUETTE Z Serum Clot Activator Tubes from 54 patients with colorectal carcinoma (CRC) and 17 patients with pancreatic adenocarcinoma. Specimens were collected from some patients on multiple occasions resulting in a total of 119 matched specimens (82 CRC and 37 pancreatic adenocarcinoma). Blood was centrifuged at 1600 x g for 10 min at room temperature to obtain plasma/serum within 3 h of collection. Plasma/serum was centrifuged at 13,000 × g for 10 min, placed in microcentrifuge tubes, and stored at -80°C. cfDNA was extracted using the QIAmp Circulating Nucleic Acid Kit and stored at 4°C until analysis. cfDNA was quantified by QuantiFluor ONE dsDNA Kit and using TapeStation. KRAS status was investigated by droplet digital PCR (ddPCR) using 67 matched plasma/serum specimens and a KRAS screening multiplex kit.
Summary of Findings
The mean concentration of DNA was higher from serum than plasma specimens (48.3 ng/mL vs 21.6 ng/mL, P<0.0001) when measured by the QuantiFluor Kit, but further investigation by TapeStation revealed no difference in concentration of DNA fragments of 50-800 bp but significantly more DNA >800 bp in serum specimens (P=0.037), indicating genomic DNA contamination. KRAS mutations were identified in a lower percentage of serum than plasma specimens (37.3% versus 46.2%, P<0.001). There were 11 plasma and 13 serum specimens with known KRAS mutations in the primary tumor but no mutation was identified in ctDNA, resulting in a sensitivity of 63.3% for plasma and 56.7% for serum. Further, the median KRAS mutation fraction was higher in plasma than serum specimens (2.9% versus 0.9%, P<0.001) but did not differ between metastatic (24 patients) and nonmetastatic (8 patients) groups. The difference in KRAS mutant fraction between the plasma and serum specimens was modestly correlated with the amount of DNA >800 bp (r=0.452, P= 0.009), the WBC count (r=0.383, p = 0.030), and the neutrophil count (r=0.465, P=0.007); indicating that cellular DNA contamination is a likely source for the underestimation of KRAS mutation frequency in serum.
Biospecimens
FluidBloodFluidPlasmaFluidSerumPreservation Types
FrozenDiagnoses
NeoplasticCarcinomaPlatforms
DNADigital PCRDNAFluorometryDNAAutomated electrophoresis/BioanalyzerPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition Metastatic diseaseNonmetastatic diseaseBiospecimen Aliquots and Components Blood and blood products PlasmaSerumDigital PCR Specific Targeted nucleic acid KRAS mutations G12A, G12C, G12D, G12V, G12R, G12S, and G13D